Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.52 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.51 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.46 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | CPB2 | Q96IY4 | 10/20 | 0.42 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.41 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.39 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.39 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4783065 | 0.94 | FOLH1 (0.45) | GSRFOLH1RNPEPSLC6A5MMP2 | |
| SCHEMBL4783069 | 0.94 | FOLH1 (0.45) | GSRFOLH1RNPEPSLC6A5MMP2 | |
| SCHEMBL1413149 | 0.87 | FOLH1 (0.53) | GSRFOLH1RNPEPSLC6A5MMP2 | |
| SCHEMBL209237 | 0.87 | FOLH1 (0.53) | GSRFOLH1RNPEPSLC6A5MMP2 | |
| SCHEMBL3727817 | 0.87 | FOLH1 (0.53) | GSRFOLH1RNPEPSLC6A5MMP2 | |
| SCHEMBL23451044 | 0.85 | FOLH1 (0.51) | GSRFOLH1RNPEPSLC6A5MMP2 | |
| SCHEMBL1116199 | 0.85 | FOLH1 (0.51) | GSRFOLH1RNPEPSLC6A5MMP2 | |
| SCHEMBL787393 | 0.85 | FOLH1 (0.51) | GSRFOLH1RNPEPSLC6A5MMP2 | |
| SCHEMBL5419504 | 0.85 | FOLH1 (0.51) | GSRFOLH1RNPEPSLC6A5MMP2 | |
| SCHEMBL29741342 | 0.85 | FOLH1 (0.51) | GSRFOLH1RNPEPSLC6A5MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442788-B2 | Antisense molecules and method of controlling expression of gene function by using the same | JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) | 2008-10-28 | — | — | US | claimed |
| US-6872809-B2 | Nucleoside derivatives | JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) | 2005-03-29 | — | — | US | claimed |
| US-20030208050-A1 | Nucleoside derivatives | JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) | 2003-11-06 | — | — | US | claimed |
| US-20030162739-A1 | Antisense molecules and method of controlling expression of gene function by using the same | JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) | 2003-08-28 | — | — | US | claimed |
| EP-1295892-A1 | ANTISENSE MOLECULES AND METHOD OF CONTROLLING EXPRESSION OF GENE FUNCTION BY USING THE SAME | Japan Science and Technology Corporation (JP) | 2003-03-26 | — | — | EP | claimed |
| EP-1295891-A1 | NUCLEOSIDE DERIVATIVES | Japan Science and Technology Corporation (JP) | 2003-03-26 | — | — | EP | claimed |
| US-7442788-B2 | Antisense molecules and method of controlling expression of gene function by using the same | JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) | 2008-10-28 | — | — | US | disclosed |
| EP-0960121-B1 | PEPTIDE NUCLEIC ACIDS HAVING ENHANCED BINDING AFFINITY, SEQUENCE SPECIFICITY AND SOLUBILITY | BUCHARDT DORTE (DK) | 2005-11-30 | — | — | EP | disclosed |
| US-6872809-B2 | Nucleoside derivatives | JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) | 2005-03-29 | — | — | US | disclosed |
| US-6872809-B2 | Nucleoside derivatives | JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) | 2005-03-29 | — | — | US | disclosed |
| EP-1295891-A4 | NUCLEOSIDE DERIVATIVES | JAPAN SCIENCE & TECH CORP (JP) | 2004-05-26 | — | — | EP | disclosed |
| US-6710164-B1 | COMPRISING AT LEAST ONE C1-C8 ALKYLAMINE SIDE CHAIN | NIELSEN PETER E (DK) | 2004-03-23 | — | — | US | disclosed |
| US-6686442-B2 | PEPTIDE NUCLEIC ACID FOR USE IN VETERINARY MEDICINE | Neilsen, Peter E. (DK) | 2004-02-03 | — | — | US | disclosed |
| WO-1998053801-A1 | CONJUGATED PEPTIDE NUCLEIC ACIDS HAVING ENHANCED CELLULAR UPTAKE | ISIS PHARMACEUTICALS, INC. (US) | 1998-12-03 | — | — | WO | disclosed |
| US-5786461-A | Peptide nucleic acids having amino acid side chains | BUCHARDT OLE (DK) | 1998-07-28 | — | — | US | disclosed |
| US-5766855-A | Peptide nucleic acids having enhanced binding affinity and sequence specificity | BUCHARDT OLE (DK) | 1998-06-16 | — | — | US | disclosed |
| US-5736336-A | Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility | BUCHARDT OLE (DK) | 1998-04-07 | — | — | US | disclosed |
| US-5719262-A | BIND COMPLEMENTARY DNA AND RNA STRANDS MORE STRONGLY | BUCHARDT OLE (DK) | 1998-02-17 | — | — | US | disclosed |
| US-5714331-A | INCORPORATING AN AMINOALKYL SIDE CHAIN INTO THE PNA'S WHICH BIND TO COMPLEMENTARY NUCLEOBASE SEQUENCES MORE TIGHTLY TO FORM ?DUPLEXES?; VIRICIDES; ANTICARCINOGENIC AGENTS; ENZYME INHIBITORS | EXXON CHEMICAL PATENT INC. | 1998-02-03 | — | — | US | disclosed |
| WO-1998003542-A1 | PEPTIDE NUCLEIC ACIDS HAVING ENHANCED BINDING AFFINITY, SEQUENCE SPECIFICITY AND SOLUBILITY | BUCHARDT, DORTE (DK) | 1998-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162739-A1 | Antisense molecules and method of controlling expression of gene function by using the same | RNGTT, RNMT, UPF1 | GSR 3049/4885FOLH1 789/4885RNPEP 1400/4885 |
| US-20030208050-A1 | Nucleoside derivatives | RIMKLA, MTHFD1, AADAT | GSR 1541/4885FOLH1 67/4885RNPEP 229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.